Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)-Pipeline Review, H1 2017
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong><br />
Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>)-<strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2017</strong><br />
1
Description:<br />
<strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>) -<br />
<strong>Hepcidin</strong> is a protein encoded by the <strong>HAMP</strong> gene. It acts by promoting endocytosis and<br />
degradation of ferrop<strong>or</strong>tin leading to the retention of iron in iron exp<strong>or</strong>ting cells and decreased<br />
flow of iron into plasma. It controls the maj<strong>or</strong> flows of iron into plasma, abs<strong>or</strong>ption of dietary<br />
iron in the intestine and recycling of iron by macrophages.<br />
<strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>)<br />
pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are<br />
developed by Companies. The molecules developed by companies in Phase II, Preclinical and<br />
Discovery stages are 2, 3 and 1 respectively. Rep<strong>or</strong>t covers products from therapy areas<br />
Hematological Dis<strong>or</strong>ders, Genetic Dis<strong>or</strong>ders, Immunology, Oncology and Toxicology which<br />
include indications Hemochromatosis, Thalassemia, Acute Inflammation, Anemia, Anemia in<br />
Chronic Kidney Disease (Renal Anemia), Anemia of Chronic Disease, Chemotherapy Induced<br />
Anemia, Iron Deficiency Anemia, Polycythemia Vera and Sickle Cell Disease.<br />
Request a sample of this rep<strong>or</strong>t @ http://www.<strong>or</strong>bisresearch.com/contacts/requestsample/310026<br />
.<br />
The latest rep<strong>or</strong>t <strong>Hepcidin</strong> - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2017</strong>, outlays comprehensive inf<strong>or</strong>mation on<br />
the <strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong><br />
<strong>HAMP</strong>) targeted therapeutics, complete with analysis by indications, stage of development,<br />
mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews<br />
key players involved in <strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong><br />
Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>) targeted therapeutics development with respective active and<br />
d<strong>or</strong>mant <strong>or</strong> discontinued projects.<br />
The rep<strong>or</strong>t is built using data and inf<strong>or</strong>mation sourced from proprietary databases,<br />
company/university websites, clinical trial registries, conferences, SEC filings, invest<strong>or</strong><br />
presentations and featured press releases from company/university sites and industry-specific<br />
third party sources.<br />
Scope<br />
- The rep<strong>or</strong>t provides a snapshot of the global therapeutic landscape f<strong>or</strong> <strong>Hepcidin</strong> (<strong>Liver</strong><br />
<strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>)<br />
- The rep<strong>or</strong>t reviews <strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong><br />
Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>)targeted therapeutics under development by companies and<br />
universities/research institutes based on inf<strong>or</strong>mation derived from company and industryspecific<br />
sources<br />
- The rep<strong>or</strong>t covers pipeline products based on various stages of development ranging from<br />
pre-registration till discovery and undisclosed stages<br />
2
- The rep<strong>or</strong>t features descriptive drug profiles f<strong>or</strong> the pipeline products which includes, product<br />
description, descriptive MoA, R&D brief, licensing and collab<strong>or</strong>ation details & other<br />
developmental activities<br />
- The rep<strong>or</strong>t reviews key players involved in <strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1<br />
<strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>)targeted therapeutics and enlists all their maj<strong>or</strong><br />
and min<strong>or</strong> projects<br />
- The rep<strong>or</strong>t assesses <strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong><br />
Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>) targeted therapeutics based on mechanism of action (MoA), route of<br />
administration (RoA) and molecule type<br />
- The rep<strong>or</strong>t summarizes all the d<strong>or</strong>mant and discontinued pipeline projects<br />
- The rep<strong>or</strong>t reviews latest news and deals related to <strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong> <strong>Antimicrobial</strong><br />
<strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>) targeted therapeutics<br />
Browse the full rep<strong>or</strong>t @ http://www.<strong>or</strong>bisresearch.com/rep<strong>or</strong>ts/index/hepcidin-liverexpressed-antimicrobial-peptide-1-<strong>or</strong>-putative-liver-tum<strong>or</strong>-regress<strong>or</strong>-<strong>or</strong>-hamp-pipelinereview-h1-<strong>2017</strong><br />
.<br />
Reasons to buy<br />
- Gain strategically significant competit<strong>or</strong> inf<strong>or</strong>mation, analysis, and insights to f<strong>or</strong>mulate<br />
effective R&D strategies<br />
- Identify emerging players with potentially strong product p<strong>or</strong>tfolio and create effective<br />
counter-strategies to gain competitive advantage<br />
- Identify and understand the targeted therapy areas and indications f<strong>or</strong> <strong>Hepcidin</strong> (<strong>Liver</strong><br />
<strong>Expressed</strong> <strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>)<br />
- Identify the use of drugs f<strong>or</strong> target identification and drug repurposing<br />
- Identify potential new clients <strong>or</strong> partners in the target demographic<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising<br />
pipeline therapeutics<br />
- Devise c<strong>or</strong>rective measures f<strong>or</strong> pipeline projects by understanding <strong>Hepcidin</strong> (<strong>Liver</strong> <strong>Expressed</strong><br />
<strong>Antimicrobial</strong> <strong>Peptide</strong> 1 <strong>or</strong> <strong>Putative</strong> <strong>Liver</strong> Tum<strong>or</strong> Regress<strong>or</strong> <strong>or</strong> <strong>HAMP</strong>)development landscape<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective<br />
partners with the most attractive projects to enhance and expand business potential and scope<br />
Companies Mentioned<br />
Daiichi Sankyo Company Ltd<br />
Noxxon Pharma AG<br />
Pieris Pharmaceuticals Inc<br />
Protagonist Therapeutics Inc<br />
Purchase a copy of this rep<strong>or</strong>t @ http://www.<strong>or</strong>bisresearch.com/contact/purchase/310026 .<br />
3
F<strong>or</strong> any enquires bef<strong>or</strong>e buying, connect with us @ enquiry@<strong>or</strong>bisresearch.com<br />
About Us:<br />
Orbis Research (<strong>or</strong>bisresearch.com) is a single point aid f<strong>or</strong> all your market research<br />
requirements. We have vast database of rep<strong>or</strong>ts from the leading publishers and auth<strong>or</strong>s across<br />
the globe. We specialize in delivering customized rep<strong>or</strong>ts as per the requirements of our clients.<br />
We have complete inf<strong>or</strong>mation about our publishers and hence are sure about the accuracy of<br />
the industries and verticals of their specialization. This helps our clients to map their needs and<br />
we produce the perfect required market research study f<strong>or</strong> our clients.<br />
Contact Us:<br />
Hect<strong>or</strong> Costello<br />
Seni<strong>or</strong> Manager – Client Engagements<br />
4144N Central Expressway,<br />
Suite 600, Dallas,<br />
Texas - 75204, U.S.A.<br />
Phone No.: +1 (214) 884-6817; +912064101019<br />
F<strong>or</strong> m<strong>or</strong>e inf<strong>or</strong>mation contact sales@<strong>or</strong>bisresearch.com<br />
4
Change language